Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ID-085 in Healthy Subjects
NCT03372629Phase 1Completed
- Sponsor
- Idorsia
- Start
- Jan 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ID-085 (4 arms), sponsored by Idorsia. Primary endpoints: Changes from baseline in PQ/PR interval, Changes from baseline in QRS interval and 8 more. Started Jan 2018; status: completed.
02
Drugs
ID-085
Beyond the preview
Go deeper on NCT03372629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03372629.